Skip to main content

Table 5 Association between G2I classes and clinico-pathological parameters

From: An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis

Clinicopathological Parameters Total n = 135 (%) G2I-1 19 G2I-2 88 G2I-3 28 χ2 test p-value
Lymph node involvement
pN0 75 (56) 12 (63) 43 (49) 20 (83) 0.086
pN+ 60 (44) 7 (37) 45 (51) 8 (29)  
Age (years)
<=55 70 (52) 8 (42) 51 (58) 11 (39) 0.149
>55 65 (48) 11 (58) 37 (42) 17 (61)  
Histological size (mm)
<= 20 90 (67) 16 (84) 57 (65) 17 (61) 0.2
> 20 45 (33) 3 (16) 31 (35) 11 (39)  
Scarff Bloom Richardson (SBR) Grade
1 25 (18) 6 (32) 15 (17) 4 (14) 0.037
2 71 (53) 12 (63) 48 (55) 11 (39)  
3 39 (29) 1 ( 5) 25 (28) 13 (39)  
Steroid Hormone Receptor status
HR+ : > = 10% 116 (86) 18 (95) 74 (84) 24 (86) 0.48
HR- 19 (14) 1 ( 5) 14 (16) 4 (14)  
Nottingham prognostic index (NPI)
1 + 2 30 (22) 6 (32) 20 (23) 4 (14) 0.37
3 85 (63) 13 (68) 50 (57) 22 (79)  
4 20 (15) 0 ( 0) 18 (20) 2 ( 7)  
Mib1
<20% 93 (69) 18 (95) 60 (68) 15 (54) 0.011
≥20% 42 (31) 1 ( 5) 28 (32) 13 (46)  
Ihc intrinsic classification(a)
LA 83 (62) 16 (84) 55 (64) 12 (43) 0.014
LB + her2+ Basal 50 (38) 3 (16) 31 (36) 16 (57)  
unclassified 2 0 2 0  
p53 status (b)
- 95 (71) 19 (100) 64 (73) 13 (46) 0.0003
+ 39 (29) 0 ( 0) 24 (27) 15 (54)  
At least one amplicon
No 71 (53) 16 (84) 47 (53) 8 (29) 0.001
Yes 64 (47) 3 (16) 41 (47) 20 (71)  
  1. (a) immunohistochemistry based on intrinsic classification, LA: luminal A, LB: luminal B, Her2: Her2-enriched; (b) TP53 mutation or immunohistochemical detection of p53 accumulation.